-
Mashup Score: 2Multiple Myeloma Patient Shines Bright as CAR T-Cell Therapy Outpatient | Dana-Farber Cancer Institute - 2 month(s) ago
Published: December 8, 2023Written by: Saul WisniaAs a systems operator who works to help maintain the electrical grid for New York state, Brian Houlihan, 46, is used to getting power to the people. But when the multiple myeloma he has lived with since 2011 stopped responding to chemotherapy, it was Houlihan who needed a recharge. … Read more
Source: blog.dana-farber.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Grants 510(k) Clearance to Sebia’s FLC Kappa, Lambda Assays for MM Diagnosis | Blood Cancers Today - 2 month(s) ago
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Multiple Myeloma, Cancer, Information, Resources - 2 month(s) ago
Information and resources about multiple myeloma from CancerCare.
Source: www.cancercare.orgCategories: General Medicine News, NursingTweet
-
Mashup Score: 3FDA Accepts BLA for Linvoseltamab in Relapsed or Refractory MM | Blood Cancers Today - 2 month(s) ago
The target action date for the FDA’s decision is August 22, 2024.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Long-term Data Supports CAR T-cells in Earlier Lines of Therapy for MM | Blood Cancers Today - 2 month(s) ago
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3Noopur Raje, MD, Discusses CAR-T in Relapsed, Refractory Myeloma | Blood Cancers Today - 2 month(s) ago
Dr. Noopur Raje shared findings on chimeric antigen receptor T-cell therapy in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
A new study found adding subcutaneous daratumumab to the standard regimen of bortezomib, lenalidomide, and dexamethasone significantly improves progression-free survival in transplant-eligible patients with newly diagnosed #MultipleMyeloma. Keep reading: https://t.co/5TegThoZfv https://t.co/IihD1jKKO7
-
-
Mashup Score: 3FDA Accepts BLA for Linvoseltamab in Relapsed or Refractory MM | Blood Cancers Today - 2 month(s) ago
The target action date for the FDA’s decision is August 22, 2024.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Adding Elotuzumab to Triplet Therapy Provides ‘No Clinical Benefit’ in Newly Diagnosed Myeloma | Blood Cancers Today - 2 month(s) ago
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Adding elotuzumab to RVd induction and consolidation therapy and lenalidomide maintenance therapy provides "no clinical benefit" in newly diagnosed #multiplemyeloma, according to a study led by @EliasKarlMai and published in @TheLancetHaem. Learn more: https://t.co/daz6XbiYrm https://t.co/OMPzdY76SN
-
-
Mashup Score: 2FDA Approves SBLA for Teclistamab in Relapsed or Refractory Myeloma | Blood Cancers Today - 3 month(s) ago
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for teclistamab (TECVAYLI®) for biweekly dosing.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
In the spring of 2023, Brian became the first #multiplemyeloma patient at Dana-Farber Brigham Cancer Center to receive outpatient CAR T-cell therapy for the disease. https://t.co/s0Mm4eoHaI